4
Changes in Ownership
Amylyx Pharmaceuticals, Inc. Filed Acc 0000899243-22-001518
Co-Chief Executive Officer acquired 75,000 shares (grant or award)
- Co-Chief Executive Officer acquired 4,870 shares (conversion)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Cohen Joshua B Co-Chief Executive Officer | 2022-01-06 | Conversion | +4,870 | 2,489,065 | D | ||
| Cohen Joshua B Co-Chief Executive Officer | 2022-01-06 | Grant or award | +75,000 | 2,564,065 | D | ||
| Derivatives | |||||||
| Cohen Joshua B Co-Chief Executive Officer | 2022-01-06 | Conversion · Series C-1 Preferred Stock | −4,870 | 0 | D | ||
| Cohen Joshua B Co-Chief Executive Officer | 2022-01-06 | Grant or award · Stock Option (right to buy) | +337,500 | 337,500 | D | ||
Loading xslF345X03/doc4.xml…